Dr. Leng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
161 Fort Washington Avenue
0
New York, NY 10032
Education & Training
- Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2013 - 2016
- UPMC Medical EducationResidency, Internal Medicine, 2009 - 2012
- State University of New York Downstate Medical Center College of MedicineClass of 2009
Certifications & Licensure
- NY State Medical License 2013 - 2026
- PA State Medical License 2012 - 2014
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 52 citationsPhase 1a/b Study of Monoclonal Antibody CAEL-101 (11-1F4) in Patients with AL AmyloidosisCamille V Edwards, Nisha Rao, Divaya Bhutani, Markus Y. Mapara, Jai Radhakrishnan
Blood. 2021-09-14 - 1 citationsReal-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia.Scott F Huntington, Enrico de Nigris, Justin T Puckett, Sachin Kamal-Bahl, Mohammed Farooqui
Cancer Medicine. 2024-01-01 - 25 citationsOne year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosisCamille V Edwards, Divaya Bhutani, Markus Y. Mapara, Jai Radhakrishnan, Sofia Shames
Amyloid. 2019-07-25
Abstracts/Posters
- Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Pha...Siyang Leng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Factors associated with over and underuse of response evaluation in elderly myeloma patients.ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- A phase 1/2 study of carfilzomib, bendamustine, and dexamethasone (CBD) in newly diagnosed multiple myeloma patients.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: